Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.53 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.53 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MC4R | P32245 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.44 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 4/20 | 0.42 |
| ▸ | HTR2A | P28223 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7291562 | 1.00 | LMNA (0.55) | LMNASMN1; SMN2HTTCYP2D6MAPT | |
| SCHEMBL28463472 | 1.00 | LMNA (0.55) | LMNASMN1; SMN2HTTCYP2D6MAPT | |
| SCHEMBL27626473 | 1.00 | LMNA (0.55) | LMNASMN1; SMN2HTTCYP2D6MAPT | |
| SCHEMBL7459001 | 1.00 | LMNA (0.55) | LMNASMN1; SMN2HTTCYP2D6MAPT | |
| SCHEMBL5453145 | 1.00 | LMNA (0.55) | LMNASMN1; SMN2HTTCYP2D6MAPT | |
| SCHEMBL879237 | 1.00 | LMNA (0.55) | LMNASMN1; SMN2HTTCYP2D6MAPT | |
| SCHEMBL1713427 | 1.00 | LMNA (0.55) | LMNASMN1; SMN2HTTCYP2D6MAPT | |
| SCHEMBL6773183 | 0.90 | CYP2D6 (0.61) | LMNASMN1; SMN2HTTCYP2D6MAPT | |
| SCHEMBL9683895 | 0.87 | CYP2D6 (0.55) | LMNASMN1; SMN2HTTCYP2D6MAPT | |
| SCHEMBL14026665 | 0.86 | CYP2D6 (0.55) | LMNASMN1; SMN2HTTCYP2D6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111808007-B | Preparation method of chiral 3-substituted pyrrolidine derivative | 青岛贞开生物医药技术有限公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-111808007-A | Preparation method of chiral 3-substituted pyrrolidine derivative | 青岛贞开生物医药技术有限公司 | 2020-10-23 | — | — | CN | disclosed |
| EP-2928888-A1 | SUBSTITUTED PYRIDOPYRAZINES AS SYK INHIBITORS | Hutchison Medipharma Limited (CN) | 2015-10-14 | — | — | EP | disclosed |
| WO-2014086316-A1 | SUBSTITUTED PYRIDOPYRAZINES AS SYK INHIBITORS | HUTCHISON MEDIPHARMA LIMITED (CN) | 2014-06-12 | — | — | WO | disclosed |
| EP-2463274-A1 | Tri-or tetra-substituted-3-aminopyrrolidine deritatives | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-06-13 | — | — | EP | disclosed |
| US-20080262075-A1 | Pyrrolidine Derivatives as Muscarinic Receptor Antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2008-10-23 | — | — | US | disclosed |
| EP-1781607-A2 | PYRROLIDINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2007-05-09 | — | — | EP | disclosed |
| WO-2006018708-A2 | PYRROLIDINE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-02-23 | — | — | WO | disclosed |
| EP-0928793-B1 | Thiazole derivatives | HOFFMANN LA ROCHE (CH) | 2002-05-15 | — | — | EP | disclosed |
| US-6001855-A | REACTING A THIAZOLE DERIVATIVE AND A CYCLIC AMINE DERIVATIVE; INHIBITS BINDING OF ADHESIVE PROTEINS TO THE SURFACE OF DIFFERENT TYPES OF CELL AND ACCORDINGLY INFLUENCE CELL-CELL AND CELL-MATRIX INTERACTIONS | HOFFMAN-LA ROCHE INC. (US) | 1999-12-14 | — | — | US | disclosed |
| EP-0928793-A1 | Thiazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1999-07-14 | — | — | EP | disclosed |
| US-5726182-A | TREATMENT OF BACTERIAL INFECTIONS | ABBOTT LABORATORIES (US) | 1998-03-10 | — | — | US | disclosed |
| US-5599816-A | BACTERICIDE | ABBOTT LABORATORIES (US) | 1997-02-04 | — | — | US | disclosed |
| WO-1996039407-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262075-A1 | Pyrrolidine Derivatives as Muscarinic Receptor Antagonists | CHRM3, CHRM2, CHRM5 | LMNA 4322/4885SMN1; SMN2 3750/4885HTT 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.